The celebrated rule change did not translate into an easy transition with Medicare Administrative Contractors or suppliers of durable medical equipment.
Word spread quickly on January 12, 2017, among the close-knit community of people who live with type 1 diabetes (T1D): after years of advocacy, appeals, and a daylong hearing with the FDA, a rule change meant Medicare would cover continuous glucose monitoring (CGM), a modern-day technology that seems perfectly suited for the age group that may no longer sense a hypoglycemic event.
Not so fast, it turns out. In recent days, word has spread just as quickly that Medicare beneficiaries are hitting snags as they try to secure the Dexcom G5, the only CGM device with an FDA approval for insulin dosing, which paved the way for Medicare’s ruling. Before the FDA approval, the Dexcom G5 was considered “adjunctive” technology, meaning it was not necessary; as of January 12, 2017, CMS has determined that it serves a therapeutic purpose, and thus can be classified as durable medical equipment.
Getting from that rule change to actual coverage is easier said than done, however. As beneficiaries get prescriptions and try to file claims for the Dexcom G5, they are running into the complex system of Medicare Administrative Contractors (MACs), who typically make coverage decisions based on Local Coverage Determinations (LCDs).
Suppliers, meanwhile are balking, because no one knows where CGM fits in the group of diabetes supplies reimbursed by Medicare, known as a “bundle.” Until CMS clarifies how it will pay for CGM, vendors do not want to risk being shortchanged for these devices. Dexcom, while a manufacturer of CGM, is not a CMS supplier, according to sources familiar with the process.
An administration source told The American Journal of Managed Care® that decisions on whether the Dexcom G5 met the test of a therapeutic CGM being “reasonable and necessary” would be addressed on a case-by-case basis, through the LCD process, or through a future National Coverage Determination.
Dexcom, meanwhile, issued a statement that it is awaiting final clarification from CMS on the documentation required to process CGM claim requests. “We are focused on finalizing this process with CMS to ensure our current and new customers get what they need,” the statement said. “We are working to resolve this situation as quickly as we can and hope to have it all resolved by summer.”
Separately, Dexcom is communicating with Medicare beneficiaries who are working to gain CGM access.
A March 28, 2017, notice said those eligible included Medicare beneficiaries with type 1 disease and those with type 2 who are on intensive insulin therapy and test blood glucose levels at least 4 times a day.
The FDA approval for dosing and the subsequent CMS ruling came after years of advocacy, by JDRF and others, including several multi-level appeals through the Medicare system. Debra Parrish, an attorney who handled the first successful case that found CMS’ statement that CGM was precautionary could not be used to block coverage, noted in an email that beneficiaries are being denied CGM coverage now even though the rule is in force.
She pointed to a May 4, 2017, notice from contractor CGS on “frequently asked questions” about CGM, that said a policy article will be “updated shortly.” In the e-mail, Parrish said the lack of certainty is “not sufficient for suppliers.” There is also uncertainty about how many test strips will be covered for those receiving a CGM.
All this is frustrating for Medicare beneficiaries living with T1D. Dan Patrick, who won a third-level appeal for a Dexcom G4, is in the worst kind of limbo—the new rule means he can’t get coverage for supplies for his old CGM, but coverage for a Dexcom G5 is in a No Man’s Land.
“What is happening? Nobody knows,” Patrick said. “There is a lack of clarity in this.”
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More